Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 6.95
NVIV's Cash to Debt is ranked higher than
77% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. NVIV: 6.95 )
NVIV' s 10-Year Cash to Debt Range
Min: 6.94   Max: No Debt
Current: 6.95

F-Score: 3
Z-Score: 4.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -165.48
NVIV's ROE (%) is ranked lower than
54% of the 448 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. NVIV: -165.48 )
NVIV' s 10-Year ROE (%) Range
Min: -775.86   Max: -195.09
Current: -165.48

-775.86
-195.09
ROA (%) -101.04
NVIV's ROA (%) is ranked lower than
53% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. NVIV: -101.04 )
NVIV' s 10-Year ROA (%) Range
Min: -1218.1   Max: 42.86
Current: -101.04

-1218.1
42.86
ROC (Joel Greenblatt) (%) -901.51
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. NVIV: -901.51 )
NVIV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3330.38   Max: -817.6
Current: -901.51

-3330.38
-817.6
EBITDA Growth (3Y)(%) -33.20
NVIV's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. NVIV: -33.20 )
NVIV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -30.7
Current: -33.2

EPS Growth (3Y)(%) -32.10
NVIV's EPS Growth (3Y)(%) is ranked higher than
58% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NVIV: -32.10 )
NVIV' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 273.3
Current: -32.1

0
273.3
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 49.60
NVIV's P/B is ranked lower than
58% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. NVIV: 49.60 )
NVIV' s 10-Year P/B Range
Min: 0   Max: 49.6
Current: 49.6

0
49.6
EV-to-EBIT -15.97
NVIV's EV-to-EBIT is ranked lower than
55% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.34 vs. NVIV: -15.97 )
NVIV' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -15.97

Current Ratio 1.63
NVIV's Current Ratio is ranked higher than
57% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.48 vs. NVIV: 1.63 )
NVIV' s 10-Year Current Ratio Range
Min: 0.14   Max: 6.67
Current: 1.63

0.14
6.67
Quick Ratio 1.63
NVIV's Quick Ratio is ranked higher than
67% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. NVIV: 1.63 )
NVIV' s 10-Year Quick Ratio Range
Min: 0.14   Max: 6.67
Current: 1.63

0.14
6.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 98.00
NVIV's Price/Net Cash is ranked higher than
78% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NVIV: 98.00 )
NVIV' s 10-Year Price/Net Cash Range
Min: 19.13   Max: 19.13
Current: 98

Price/Net Current Asset Value 98.00
NVIV's Price/Net Current Asset Value is ranked higher than
67% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NVIV: 98.00 )
NVIV' s 10-Year Price/Net Current Asset Value Range
Min: 17.66   Max: 17.66
Current: 98

Price/Tangible Book 49.00
NVIV's Price/Tangible Book is ranked lower than
53% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.75 vs. NVIV: 49.00 )
NVIV' s 10-Year Price/Tangible Book Range
Min: 3.96   Max: 19.38
Current: 49

3.96
19.38
Earnings Yield (Greenblatt) -6.50
NVIV's Earnings Yield (Greenblatt) is ranked higher than
55% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. NVIV: -6.50 )
NVIV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -29.4   Max: 1000
Current: -6.5

-29.4
1000

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting Mar 27 2015
InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for... Mar 26 2015
InVivo Therapeutics Announces Keck Hospital of University of Southern California as New Site for... Mar 25 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Material Modification to Rights of Security... Mar 24 2015
InVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Mar 24 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Financials Mar 18 2015
InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update Mar 11 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-K, Annual Report Mar 11 2015
InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial... Feb 23 2015
InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial... Feb 23 2015
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer Feb 09 2015
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer Feb 09 2015
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board Feb 05 2015
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board Feb 05 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Jan 29 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 29 2015
InVivo Therapeutics Announces $12 Million Registered Direct Offering Jan 29 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure Jan 26 2015
InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial Jan 22 2015
NVIV: InVivo Patient No.1 Shows ‘Unexpected’ Gains Jan 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK